Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/65644
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Requirement for additional treatment for dogs with atopic dermatitis undergoing allergen-specific immunotherapy
Author: Colombo, S.
Hill, P.
Shaw, D.
Thoday, K.
Citation: Veterinary Record, 2007; 160(25):861-864
Publisher: British Veterinary Assoc
Issue Date: 2007
ISSN: 0042-4900
2042-7670
Statement of
Responsibility: 
S. Colombo, P. B. Hill, D. J. Shaw, K. L. Thoday
Abstract: Allergen-specific immunotherapy (asit) is one of the main treatments for atopic dermatitis in dogs, but it often requires additional treatments such as antibacterial and antifungal therapy for secondary bacterial and yeast infections, or antipruritic drugs to control the clinical signs or treat the adverse effects of the immunotherapy. Twenty-seven dogs enrolled in a study of asit were clinically assessed four times over a period of nine months; their requirement for treatment for secondary bacterial and yeast infections, for the administration of glucocorticoids as additional antipruritic therapy, and for the treatment of any adverse effects of the asit were evaluated. Twenty (74 per cent) of the dogs were treated for superficial bacterial pyoderma, 18 (66·6 per cent) required treatment for Malassezia species dermatitis on one or more occasions, eight (29·6 per cent) required treatment for otitis externa due to Malassezia species or bacteria, and eight required glucocorticoids to control their clinical signs. Five (18·5 per cent) of the dogs experienced adverse effects due to the asit and two required treatment with antihistamines (H1 receptor antagonists) in order to continue with the asit.
Rights: Copyright © 2011 British Veterinary Association. All rights reserved.
RMID: 0020103499
DOI: 10.1136/vr.160.25.861
Appears in Collections:Animal and Veterinary Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.